109. Atypical hemolytic uremic syndrome
95 clinical trials, 27 drugs (DrugBank: 5 drugs), 2 drug target genes, 9 drug target pathways
Searched query = "Atypical hemolytic uremic syndrome", "aHUS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-004129-18-LT (EUCTR) | 15/03/2019 | 29/01/2019 | An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from their initial study | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: COVERSIN | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom;India | ||
| 2 | EUCTR2016-004129-18-NL (EUCTR) | 14/02/2018 | 16/11/2017 | An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initial study | CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Coversin Product Code: rVA576 INN or Proposed INN: COVERSIN Other descriptive name: COVERSIN | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | Argentina;Poland;Lithuania;Netherlands;United Kingdom | ||
| 3 | EUCTR2017-000064-15-GB (EUCTR) | 14/09/2017 | 28/06/2017 | A study of Safety and Efficacy of Coversin in adult aHUS subjects | A Phase 2, single arm study of Safety and Efficacy of Coversin in adult aHUS subjects | Atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 20.0;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Akari Therapeutics Plc | ,NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | United Kingdom | |||
| 4 | EUCTR2016-004129-18-GB (EUCTR) | 17/03/2017 | 21/12/2016 | An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from their initial study | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: rVA576 | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom | ||
| 5 | NCT03829449 (ClinicalTrials.gov) | March 13, 2017 | 20/12/2018 | rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal Nocturnal Hemoglobinuria;Atypical Hemolytic Uremic Syndrome | Drug: rVA576 (Coversin) | AKARI Therapeutics | NULL | Recruiting | 18 Years | N/A | All | 50 | Phase 3 | Poland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2016-004129-18-PL (EUCTR) | 07/03/2017 | 18/01/2017 | An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initial study | CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 21.1;Level: PT;Classification code 10018932;Term: Haemolytic uraemic syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 21.1;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: rVA576 (Coversin) Product Code: rVA576 INN or Proposed INN: rVA576 (COVERSIN) Other descriptive name: rVA576 (COVERSIN) | Akari Therapeutics Plc | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom |